PDS Biotechnology Co. (NASDAQ:PDSB) Stock Position Reduced by Inspirion Wealth Advisors LLC

Inspirion Wealth Advisors LLC lessened its stake in PDS Biotechnology Co. (NASDAQ:PDSB) by 4.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 344,394 shares of the company’s stock after selling 15,500 shares during the quarter. Inspirion Wealth Advisors LLC’s holdings in PDS Biotechnology were worth $1,316,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Kathleen S. Wright Associates Inc. acquired a new position in PDS Biotechnology in the first quarter worth approximately $28,000. Tempus Wealth Planning LLC acquired a new stake in PDS Biotechnology in the second quarter valued at approximately $55,000. Ground Swell Capital LLC bought a new stake in PDS Biotechnology in the second quarter worth approximately $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of PDS Biotechnology during the 2nd quarter worth $115,000. Finally, Squarepoint Ops LLC bought a new position in shares of PDS Biotechnology during the 2nd quarter valued at $120,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on PDSB shares. HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of PDS Biotechnology in a research report on Wednesday. B. Riley lowered their price objective on PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, June 12th. Finally, Alliance Global Partners upgraded PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.25.

PDS Biotechnology Stock Performance

Shares of PDSB stock traded down $0.25 during trading hours on Friday, reaching $3.71. 719,878 shares of the company’s stock were exchanged, compared to its average volume of 644,373. PDS Biotechnology Co. has a fifty-two week low of $2.53 and a fifty-two week high of $6.85. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $136.08 million, a P/E ratio of -2.73 and a beta of 1.88. The business has a fifty day moving average price of $3.24 and a 200-day moving average price of $3.35.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.08. During the same quarter in the prior year, the company posted ($0.37) EPS. Analysts predict that PDS Biotechnology Co. will post -1.3 EPS for the current fiscal year.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.